Matteucci Claudia, Grelli Sandro, Balestrieri Emanuela, Minutolo Antonella, Argaw-Denboba Ayele, Macchi Beatrice, Sinibaldi-Vallebona Paola, Perno Carlo Federico, Mastino Antonio, Garaci Enrico
Department of Experimental Medicine & Surgery, University of Rome 'Tor Vergata', Via Montepellier, 1, Rome 00133, Italy.
Department of System Medicine, University of Rome 'Tor Vergata', Via Montepellier, 1, Rome 00133, Italy.
Future Microbiol. 2017 Feb;12:141-155. doi: 10.2217/fmb-2016-0125. Epub 2017 Jan 20.
In spite of the consistent benefits for HIV-1 infected patients undergoing antiretroviral therapy, a complete immune reconstitution is usually not achieved. Actually, antiretroviral therapy may be frequently accompanied by immunological unresponsiveness, persistent inflammatory conditions and inefficient cytotoxic T-cell response. Thymosin alpha 1 is a thymic peptide that demonstrates a peculiar ability to restore immune system homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.
尽管接受抗逆转录病毒疗法的HIV-1感染患者持续受益，但通常无法实现完全的免疫重建。实际上，抗逆转录病毒疗法可能经常伴随着免疫无反应性、持续性炎症状态和低效的细胞毒性T细胞反应。胸腺肽α1是一种胸腺肽，在不同的生理和病理条件（即感染、癌症、免疫缺陷、疫苗接种和衰老）下，作为一种依赖于宿主炎症状态或免疫功能障碍的多任务蛋白，具有恢复免疫系统稳态的特殊能力。本综述报告了关于胸腺肽α1在HIV-1感染中的体外和体内研究的现有知识。讨论了治疗干预的最新发现和未来前景。
